Plasma and Brain Levels of Terpene Trilactones in Rats after an Oral Single Dose of Standardized Ginkgo biloba Extract EGb 761®

Abstract

Several studies indicate that the terpene trilactones (TTL) of EGb 761® are responsible for most of its pharmacological action in the brain [1]. Therefore, we investigated the ability of the TTL to cross the blood brain barrier in rats after a single oral administration (600 mg/kg) of EGb 761® and compared it with the plasma levels. In addition, we checked the pharmacokinetic characteristics of an application of EGb 761® against a similar amount of pure substances. For this purpose, we developed a sensitive HPLC-(APCI)-MS method for the determination of the Ginkgo biloba TTL (ginkgolide A [GA], B [GB], C [GC] and bilobalide [Bb]) in plasma as well as in brain tissue. The following animal study shows that the oral application of 600 mg/kg EGb 761® results in significant GA, GB, and Bb concentrations in plasma as well as in the CNS of the rodents, while the GC concentration was below the detection limit of the analytical method in both matrices. GA, GB, and Bb brain concentrations showed a rapid increase up to 55 ng/g, 40 ng/g, and 98 ng/g with no difference of the characteristic after extract or pure substance application. Regarding the plasma levels, significant higher C_max and AUC values were detected after application of the extract EGb 761®. These results allow for the first time a discussion of pharmacological effects with the knowledge of the pharmacokinetic behavior of the TTL in target tissues.

Key words

Ginkgo biloba - Ginkgoaceae - terpene trilactones - CNS - ginkgolides - bilobalide

References

• 1 Ramassamy C, Longpre F, Christen Y. Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?.  Curr Alzheimer Res. 2007;  4 253-262
• 2 van Beek T A. Chemical analysis of Ginkgo biloba leaves and extracts.  J Chromatogr A. 2002;  967 21-55
• 3 IQWiG .IQWiG Abschlussbericht: Ginkgohaltige Präparate bei Alzheimer Demenz. Köln; IQWiG 2008
• 4 Blecharz-Klin K, Piechal A, Joniec I, Pyrzanowska J, Widy-Tyszkiewicz E. Pharmacological and biochemical effects of Ginkgo biloba extract on learning, memory consolidation and motor activity in old rats.  Acta Neurobiol Exp (Wars). 2009;  69 217-231
• 5 Abdel-Kader R, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A, Muller W E. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761).  Pharmacol Res. 2007;  56 493-502
• 6 Leuner K, Hauptmann S, Abdel-Kader R, Scherping I, Keil U, Strosznajder J B, Eckert A, Muller W E. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease?.  Antiox Redox Signal. 2007;  9 1659-1675
• 7 Eckert A, Keil U, Scherping I, Hauptmann S, Muller W E. Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract EGb 761.  Ann N Y Acad Sci. 2005;  1056 474-485
• 8 Kiewert C, Kumar V, Hildmann O, Hartmann J, Hillert M, Klein J. Role of glycine receptors and glycine release for the neuroprotective activity of bilobalide.  Brain Res. 2008;  1201 143-150
• 9 Fehske C J, Leuner K, Muller W E. Ginkgo biloba extract (EGb761) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment.  Pharmacol Res. 2009;  60 68-73
• 10 Moreau J P, Eck C R, McCabe J, Skinner S. Absorption, distribution and elimination of a labelled extract of Ginkgo biloba leaves in the rat.  Presse Med. 1986;  15 1458-1461
• 11 Rangel-Ordóñez L, Nöldner M, Schubert-Zsilavecz M, Wurglics M. Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761®.  Planta Med. DOI: 10.1055/s-0030-1249962 , advance online publication May 19, 2010
  
• 12 Fourtillan J B, Brisson A M, Girault J, Ingrand I, Decourt J P, Drieu K, Jouenne P, Biber A. Pharmacokinetic properties of bilobalide and ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761).  Therapie. 1995;  50 137-144
• 13 Biber A. Pharmacokinetics of Ginkgo biloba extracts.  Pharmacopsychiatry. 2003;  36 (Suppl. 1) S32-S37
• 14 Mauri P, Pozzi F, Basilico F, Riva A, Morazzoni P, Bombardelli E, Rossoni G Palma A de. LC-MS characterization of terpene lactones in plasma of experimental animals treated with Ginkgo biloba extracts correlation with pharmacological activity.  J Pharm Biomed Anal. 2006;  40 763-768
• 15 Xie J, Ding C, Ge Q, Zhou Z, Zhi X. Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats.  J Chromatogr B Anal Technol Biomed Life Sci. 2008;  864 87-94
• 16 Rossi R, Basilico F, Rossoni G, Riva A, Morazzoni P, Mauri P L. Liquid chromatography/atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex.  J Pharm Biomed Anal. 2009;  50 224-227
• 17 Biber A, Koch E. Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS.  Planta Med. 1999;  65 192-193
• 18 Ding S, Dudley E, Song Q, Plummer S, Tang J, Newton R P, Brenton A G. Mass spectrometry analysis of terpene lactones in Ginkgo biloba.  Rapid Commun Mass Spectrom. 2008;  22 766-772
• 19 Sora D I, Stefanescu V, David V, Medvedovici A. Validation of an LC-MS/MS assay of terpene trilactones in Ginkgo biloba extracts and pharmaceutical formulations through standard addition method.  J Pharm Biomed Anal. 2009;  50 459-468
• 20 Butterweck V, Liefländer-Wulf U, Winterhoff H, Nahrstedt A. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats.  Planta Med. 2003;  69 189-192
• 21 Eckert A, Keil U, Kressmann S, Schindowski K, Leutner S, Leutz S, Muller W E. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress.  Pharmacopsychiatry. 2003;  36 (Suppl. 1) S15-S23
• 22 Bate C, Tayebi M, Williams A. Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro.  Mol Neurodegener. 2008;  3 1
• 23 Kondratskaya E L, Fisyunov A I, Chatterjee S S, Krishtal O A. Ginkgolide B preferentially blocks chloride channels formed by heteromeric glycine receptors in hippocampal pyramidal neurons of rat.  Brain Res Bull. 2004;  63 309-314
• 24 Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract.  Cell Mol Life Sci. 2003;  60 1779-1792
• 25 Klein J, Chatterjee S S, Loffelholz K. Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba.  Brain Res. 1997;  755 347-350
• 26 Weichel O, Hilgert M, Chatterjee S S, Lehr M, Klein J. Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus.  Naunyn Schmiedebergs Arch Pharmacol. 1999;  360 609-615
• 27 Kiewert C, Kumar V, Hildmann O, Rueda M, Hartmann J, Naik R S, Klein J. Role of GABAergic antagonism in the neuroprotective effects of bilobalide.  Brain Res. 2007;  1128 70-78